Texas is currently home to 4849 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/05/2025
Locations: Neurology Consultants of Dallas - Lyndon B Johnson Freeway- Site Number : 8400152, Dallas, Texas
Conditions: Multiple Sclerosis
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Recruiting
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/05/2025
Locations: Novel Research LLC, Bellaire, Texas
Conditions: Systemic Lupus Erythematosus
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
Recruiting
The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/05/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Acquired Antithrombin Deficiency
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Recruiting
To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Large B-cell Lymphoma
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Recruiting
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/05/2025
Locations: Research Site, Houston, Texas
Conditions: Hepatocellular Carcinoma (HCC)
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Recruiting
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors. The goal of this clinical trial is to learn whether NPX267 is safe and tolerable in patients whose cancers are known to express HHLA2 including epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. The main questions it aims to answer are: * what is an appropriate dose to be given to patients? * are the side effects of treatment manageab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Malignant Neoplasm
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Recruiting
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/05/2025
Locations: Xentria Investigative Site, Houston, Texas
Conditions: Pulmonary Sarcoidosis
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Recruiting
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis). or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possib... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Investigational Site (118), Colleyville, Texas
Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers
Recruiting
This phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the body (metastatic), cannot be removed by surgery (unresectable) or that has come back after a period of responding to prior therapy (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
Recruiting
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/05/2025
Locations: Accurate Clinical Research Research, Baytown, Texas
Conditions: Systemic Lupus Erythematosus
ALTERRA Post-Approval Study
Recruiting
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
Gender:
ALL
Ages:
All
Trial Updated:
03/05/2025
Locations: Medical City Dallas, Dallas, Texas
Conditions: Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
A Study of XMT-1660 in Participants With Solid Tumors
Recruiting
A Study of XMT-1660 in Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Texas Oncology, P.A., Dallas, Texas
Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma